Table 2

Toxicity and efficacy outcomes of arm A and arm B at interim analysis

Arm A (n = 21)Arm B (n = 21)
Efficacy   
    No. of cycles, median (range) 2 (1-10) 1 (1-6) 
    No. (%) of patients receiving second cycle 14 (67) 9 (43) 
    Median OS, mo (range) 12 (0.5-37.4) 7 (0.6-22.5) 
        OS > 12 mo, no. (%) 10 (48) 7 (33) 
    CR, no. (%) 7 (33) 6 (29) 
        Median DFS, mo (range) 11 (6.6-27.1) 8 (2.2-21.2) 
        OS > 12 mo, no. (%) 6 (86) 5 (83) 
Overall Toxicity Score, no. (%)*   
    0 7 (33) 4 (19) 
    1 6 (29) 5 (24) 
    2 6 (29) 5 (24) 
    3 1 (5) 2 (10) 
    4 1 (5) 5 (24) 
    No. (%) of Toxicity Score > 3 2 (10) 7 (33) 
    No. (%) > grade 3 nonhematologic toxicities 4 (19) 7 (33) 
    No. (%) > grade 3 infection 5 (24) 8 (38) 
        Bloodstream 
        Lung 
        Fatal infection 1 (5) 4 (19) 
Arm A (n = 21)Arm B (n = 21)
Efficacy   
    No. of cycles, median (range) 2 (1-10) 1 (1-6) 
    No. (%) of patients receiving second cycle 14 (67) 9 (43) 
    Median OS, mo (range) 12 (0.5-37.4) 7 (0.6-22.5) 
        OS > 12 mo, no. (%) 10 (48) 7 (33) 
    CR, no. (%) 7 (33) 6 (29) 
        Median DFS, mo (range) 11 (6.6-27.1) 8 (2.2-21.2) 
        OS > 12 mo, no. (%) 6 (86) 5 (83) 
Overall Toxicity Score, no. (%)*   
    0 7 (33) 4 (19) 
    1 6 (29) 5 (24) 
    2 6 (29) 5 (24) 
    3 1 (5) 2 (10) 
    4 1 (5) 5 (24) 
    No. (%) of Toxicity Score > 3 2 (10) 7 (33) 
    No. (%) > grade 3 nonhematologic toxicities 4 (19) 7 (33) 
    No. (%) > grade 3 infection 5 (24) 8 (38) 
        Bloodstream 
        Lung 
        Fatal infection 1 (5) 4 (19) 
*

Overall Toxicity Scoring Criteria: 0 indicates no toxicity; 1, any toxicity (hospitalization < 10 days; fever/infection; grade 1 or 2 mucositis, elevated bilirubin, or creatinine; grade 1 neurotoxicity); 2, hospitalization > 10 days; grade 2 neurotoxicity; all other toxicities grade 3; 3, neurotoxicity > grade 3; all other toxicities grade 4; and 4, death.

or Create an Account

Close Modal
Close Modal